Loading
A phase 1/2 trial of CNA3103: 5 x 10^7 cells in colorectal cancer, run by Carina Biotech Limited, now recruiting.
A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer is a phase 1/2 interventional study registered as NCT05759728 by Carina Biotech Limited, with 45 participants planned, started 2023-10-24 and due to reach its primary completion in 2027-12. Interventions recorded: CNA3103: 5 x 10^7 cells, CNA3103: 1.5 x 10^8 cells, CNA3103: 4.5 x 10^8 cells, CNA3103: 1.5 x 10^9 cells, CNA3103: 2.5 x 10^7 cells and CNA3103: 6.75 × 10^8 cells.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/